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Abstract: Recombinant adenovirus type 5 (rAd) has been used as a vaccine platform against many
infectious diseases and has been shown to be an effective vaccine vector. The dose of the vaccine
varies significantly from study to study, making it very difficult to compare immune responses and
vaccine efficacy. This study determined the immune correlates induced by serial dilutions of rAd
vaccines delivered intramuscularly (IM) and intranasally (IN) to mice and rats. When immunized
IM, mice had substantially higher antibody responses at the higher vaccine doses, whereas, the IN
immunized mice showed a lower response to the higher rAd vaccine doses. Rats did not show
dose-dependent antibody responses to increasing vaccine doses. The IM immunized mice and rats
also showed significant dose-dependent T cell responses to the rAd vaccine. However, the T cell
immunity plateaued in both mice and rats at 109 and 1010 vp/animal, respectively. Additionally,
the highest dose of vaccine in mice and rats did not improve the T cell responses. A final vaccine
analysis using a lethal influenza virus challenge showed that despite the differences in the immune
responses observed in the mice, the mice had very similar patterns of protection. This indicates
that rAd vaccines induced dose-dependent immune responses, especially in IM immunized animals,
and that immune correlates are not as predictive of protection as initially thought.
Keywords: dose-dependent response; antibody; T Cell; hemagglutinin; influenza; vaccine;
recombinant adenovirus; viral vector

1. Introduction
Adenoviruses are naked icosahedral viruses with linear double-stranded genomes of ~31 Kbp
to 45 Kbp. There are over 65 characterized subtypes of human adenoviruses that are divided into
seven different species (A–G), based on whole genome sequencing [1]. Adenoviruses exist in many
species of animals, including human, bovine, ovine, nonhuman primate, canine, murine, turkey,
frog and more [2–8]. Adenoviruses were among the first viruses to be used for gene delivery [9].
Since adenoviruses are double-stranded DNA viruses, they lend themselves quite well to cloning and
manipulation by molecular biology. Cells expressing the early E1 adenovirus genes, as well as other
genes, in trans have made it possible to produce replication-defective adenovirus that have a much
safer profile than wildtype adenoviruses [10,11]. To date, recombinant adenoviruses (rAd) are the
most studied viral gene delivery vectors. Therefore, adenoviruses are one of the most commonly used
viruses for gene delivery, vaccination, gene therapy and anti-cancer, or oncolytic activity [7,10–19].
In support of the use of adenoviruses in research, a PubMed search for adenovirus results in more than
53,000 publications over the past 65 years. A search of the clinical trials database for adenovirus results
in 528 ongoing or completed human clinical trials.
Adenovirus has been studied extensively for use as a vector for vaccination. Preclinical and clinical
studies have shown efficacy using adenovirus to vaccinate against Ebola, influenza virus, human
immunodeficiency virus (HIV), malaria, tuberculosis, and many more [12,20–23]. However, a major
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drawback to using human adenoviruses in humans is the presence of pre-existing immunity [24–27].
Pre-existing immunity can seriously impair the use of an adenovirus and, in one case, may have
increased the rate of infection as compared to the placebo group [28–30]. Therefore, many scientists
have turned to using low seroprevalent human adenoviruses or animal viruses [25,31–35]. Many of
these low seroprevalent adenoviruses are now being actively pursued as vaccine vectors, and much of
this work is being pursued in preclinical trials using small animal rodent models. Most of the studies
using rAd as a vaccine have focused on prophylaxis, or the prevention of disease. However, recent
studies have highlighted the fact that rAd vaccines can be used effectively as therapeutics. Studies have
shown that rAd vaccines can accelerate the control of tuberculosis, they can be used to refocus T cell
responses towards conserved HIV-1 epitopes and have shown efficacy in preclinical trials to resolve
hepatitis C virus in a rat model where viremia was terminated within 14 days of virus challenge [36–38].
In addition, there have been many attempts to modify rAd vaccines to improve vaccine efficacy and
oncolytic activity. Examples of these modifications include targeting, hexon-display, and polyethylene
glycol shielding [39–42].
Throughout the literature, there are inconsistencies in how much rAd vector is used to vaccinate
a mouse and by what route the rAd vaccine be should administered. For example, one study may
report the use of 108 pfu/mouse delivered intranasally, while another may report 108 virus particles
(vp)/mouse delivered intramuscularly. It is difficult to compare these responses. We asked the question:
does the vaccine dose have a significant effect on the immune response generated and is the route
by which the vaccine delivered important? In this study, we examined the dose response to rAd
expressing the HIV gag gene in both mice and rats by both the intramuscular (IM) and intranasal (IN)
route. Lastly, we looked at the dose response of mice immunized with a rAd-influenza virus vaccine by
both routes and administered a lethal challenge virus in order to determine if the mice were protected.
We show that the dose and the route are very important when it comes to immune correlates. However,
immune correlates do not always correlate with protection.
2. Materials and Methods
2.1. Adenovirus Production
The replication defective (E1/E3 deleted) Ad5 vectors used in these studies were constructed using
the Ad-Easy system in low passage 293 cells as previously described [43]. The Ad-gag viral vector
expressed the p55 codon-optimized gag gene of HIV-1 strain HXB2 (Ad-gag) (Genscript, Piscataway,
NJ, USA). The Ad-PR vaccine expressed the human codon-optimized hemagglutinin (HA) from the
H1N1 influenza virus strain A/Puerto Rico/8/1934 (H1N1) virus (Genscript). All adenoviruses were
purified using ultracentrifugation on two sequential CsCl gradients. Step gradients were created
using 1.4 g/mL, 1.3 g/mL and 1.2 g/mL of cesium chloride in Ad-Tris buffer. Cell lysates were loaded
onto the cesium chloride step gradients and continuous gradients were formed using an SW32ti
rotor in a Beckman Coulter Optima L100-XP at 26,000 RPM for two hours, followed by a second
gradient overnight. The banded viruses were extracted from the cesium chloride with an 18-gauge
needle and desalted using a PD-10 column (BioRad, Hercules, CA, USA) and Tris buffer containing
10% glycerol. The viruses were quantitated by OD260 using a NanoDrop Lite Spectrophotometer
(ThermoFisher). The final concentration of rAd particles was determined as 1012 virus particles (vp)/ 1
OD260, as previously described [44].
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2.2. Animals
Female inbred mice and rats are the most common small animal models for preclinical rAd vaccine
studies because they are less aggressive and can be group housed. Therefore, we used female BALB/c
mice (6–8 weeks old) and Sprague Dawley rats (9 weeks old) that were purchased from Charles River
Laboratories (Wilmington, MA, USA). The mice were housed in the University of Nebraska, Lincoln
(UNL) Life Sciences Annex under the Association for Assessment and Accreditation of Laboratory
Animal Care (AALAC) guidelines with animal use protocols approved by the corresponding the UNL
Institutional Animal Care and Use Committee (IACUC protocol No. 1217). Rats were housed in the
Mayo Clinic Animal Facility under the Association for Assessment and Accreditation of Laboratory
Animal Care (AALAC) guidelines with animal use protocols approved by the Mayo Clinic Animal
Use and Care Committee, protocol A24111. All animal experiments were carried out according to the
provisions of the Animal Welfare Act, PHS Animal Welfare Policy, the principles of the NIH Guide for
the Care and Use of Laboratory Animals, and the policies and procedures of UNL and Mayo Clinic
Office of Research Institutional Animal Care Program (IACP).
2.3. Immunizations
Groups of 5 female BALB/c mice were anesthetized i.p. with ketamine (140 mg/kg)/xylazine
(5.55 mg/kg) diluted in sterile ddH2 O. The immunization consisted of 107 to 1010 vp of recombinant
adenovirus (rAd) expressing either the HIV-1 gag gene or the influenza virus HA gene. The virus
was injected intramuscularly using a 27-gauge needle into both quadriceps in two 25 µL injections.
For intranasal immunization, the mice were similarly anesthetized and placed on their back. Virus was
pipetted into the nares in two 10-microliter instillations. The rats were anesthetized with isofluorane
using 5% for induction and 2% for maintenance. For rats, the immunization consisted of 109 to 1011
vp of rAd-gag. Groups of 3 female rats were immunized intramuscularly using a 27-gauge needle
into both quadriceps in two 50 µL injections. Sera and splenocytes from mice and rats were harvested
3 weeks post-immunization for ELISpot and ELISA.
2.4. Statistical Analysis
Prism 5 version 5.0d (GraphPad software, San Diego, CA, USA) was used to analyze all data.
Data are expressed as the mean with standard error (SEM). ELISA and T-cell data were analyzed using
one-way ANOVA with Bonferroni comparing all pairs of columns. A p value < 0.05 was considered
statistically significant (* p < 0.05; ** p < 0.01; *** p < 0.001).
2.5. Enzyme Linked Immunosorbent Assay (ELISA)
We performed ELISA assays in order to determine the anti-gag immune humoral immunity
induced by the Ad-gag vaccine at various doses. The antibody quantitation was performed as
previously described [45]. Briefly, Immulon 4 HBX plates (Thermo Fisher, Grand Island, NY, USA)
were coated with 100 µL of HIV-1 gag protein (NIH AIDS Reagent and Repository) at a concentration
of 1 µg/mL in PBS for 2 hours at room temperature (RT). The plates were blocked for 1 hour with BSA
at 2 mg/mL for 1 hour at room temperature and used immediately or frozen for later use. The sera
were diluted 1:100 in PBS, with BSA (1 mg/mL) and added to the plate for 1 hour at RT. The plates
were washed 6 times with 200 µL of PBS. An amount of 100 µL of goat anti-mouse HRP conjugated
antibody (Pierce, Rockford, IL, USA) was diluted 1:2000 in PBS with BSA (1 mg/mL) was added to
each well. The ELISA on rat sera was performed identically to the mouse ELISA, with the exception
that rat antibodies were detected using goat anti-rat IgG H&L (HRP) (Abcam, Cambridge, MA, USA).
The plate was incubated at room temperature for 1 h. After washing 4× with PBST and 2× with PBS,
the plate was developed with 1-Step Ultra TMB-ELISA (Thermo Fisher, Grand Island, NY, USA), and
the reaction was stopped with 2 M sulfuric acid. The OD450 was determined using a SpectraMax i3x
Multi-Mode microplate reader (Molecular Devices, San Jose, CA, USA).
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2.6. Enzyme-Linked Immune Spot (ELISpot) Assay
The ELISpot assay was performed as previously described [46]. Briefly, splenocytes were prepared
from immunized mice and rats using a 70-µm cell strainer. The splenocytes were forced through the
strainer using the plunger from a 5 mL syringe (Becton Dickinson, Franklin Lakes, NJ, USA) and the red
blood cells were lysed using an ACK lysis buffer consisting of NH4 Cl (8024 mg/L), KHCO3 (1001 mg/L)
and EDTA Na2 ·2H2 O (3.722 mg/L) in ddH2 O and filter-sterilized. The splenocytes were washed and
resuspended in cRPMI-10% FBS. The splenocytes were mixed with overlapping peptides representing
the HIV-1 consensus B gag gene (NIH AIDS Reagent and Repository) and added to 96-well Immulon-P
filter plates (Millipore, Temecula, CA, USA) that had been coated with anti-mouse interferon-γ
(IFN-γ) AN18 antibody (MABTECH). The plates were incubated at 37 ◦ C with 5% CO2 overnight.
The plates were washed and mouse IFN-γ-producing cells were detected using R4-6A2 antibody and
streptavidin-ALP (MABTECH). Rat IFN-γ cells were detected using the capture monoclonal antibody
rIFN-γ-I and detected using the secondary biotinylated monoclonal antibody rIFN-γ-II (MABTECH).
A streptavidin-alkaline phosphatase was used to detect the biotinylated antibody. The spots were
developed using BCIP/NBT substrate (Moss, Pasadena, MD, USA). The air-dried plates were counted
using an automated ELISpot plate reader (AID iSpot Reader Spectrum, Oceanside, CA, USA). Results
are expressed as spot-forming cells (SFC) per 106 splenocytes.
2.7. Influenza Virus Challenge
The mice were subjected to a stringent lethal challenge 3 weeks after vaccination with various
doses of Ad-PR delivered by either the intramuscular or intranasal route. A/Puerto Rico/8/1934 (H1N1)
virus was grown in specific pathogen-free egg chorioallantoic fluid. The mouse 50% lethal dose
(MLD50 ) was determined by inoculating mice intranasally with serial dilutions of the virus stock
and determining the endpoint as death or a weight loss of ≥30%. The lethal virus was administered
intranasally into mice that were anesthetized i.p. with ketamine (140 mg/kg)/xylazine (5.55 mg/kg)
diluted in sterile ddH2 O. The mice were placed in a supine position and 20 µL of influenza virus was
pipetted into the nares in two 10 µL volumes. Baseline weight measurements were determined prior to
the lethal influenza virus challenge. The vaccinated mice received 100 MLD50 of A/Puerto Rico/8/1934
(H1N1) virus. Body weight and signs of disease were observed daily. Mice were humanely euthanized
if their body weight dropped ≥25% of baseline weights.
3. Results
3.1. Antibody Dose-Dependent Responses in Mice
A stronger dose response was observed in the IM immunized mice as compared to the
IN immunized mice, where the dose had statistically significant impacts on the induction of
vaccine-induced antibody (Figure 1). The antibody response was greater in the 108 vp group as
compared to the 107 vp group (p = 0.05) and the 1010 vp group was significantly greater than the 108
vp group (p = 0.001) (Figure 1A). In contrast, the IN dose had less of an effect on the induction of
vaccine-induced antibodies (Figure 1B). However, there were some statistically significant differences.
The 1010 vp group had greater antibody levels as compared to the 108 vp group (p = 0.01) and the 109
vp group was greater than the 107 vp group (p = 0.05).
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3.3. Antibody and T Cell Dose-Dependent Responses in Rats
There were no statistically significant dose responses to vaccine-induced antibodies in IM
immunized rats (Figure 3A). Rats vaccinated with 109 vp induced the same levels of anti-gag
antibodies as rats immunized with 1011 vp of vaccine. However, there was a dose-dependent
response observed in the T cells of rats immunized with 1010 vp/rat (Figure 3B). Although there were
no statistically significant differences observed, the 1010 vp group had the highest levels of anti-gag T
cell immunity. Interestingly, increasing the dose to 1011 vp/rat did not increase the antigen-specific T
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and death in both groups (Figure 4). There was slightly more weight loss in the IN group immunized
with 5 × 106 vp than in the IM immunized group (Figure 4C). However, the survival was the same at
80% (Figure 4D). One mouse in the 1 × 106 vp/mouse IM immunized group survived the challenge
(Figure 4B), whereas all the 1 × 106 vp/mouse IN immunized mice died (Figure 4C). This could
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4. Discussion
Many preclinical studies using rAd as a vaccine in rodent models use very high doses of rAd
for vaccination. This increases the likelihood that the results will be positive. However, many of
these doses are too large to be translated into human equivalent doses. For example, based on an
average weight of 75 kg for a human, the equivalent dose of 1 × 1010 vp, as determined in a 20-gram
mouse, would be 3.75 × 1013 vp/vaccine in a human. This dose is beyond the current capacity of rAd
production. However, that direct translation, based solely on weight, may not be accurate. Rats are
more than 10 times the size of mice and yet there are no differences between antibodies induced at
109 vp/rat versus 1011 vp/rat. However, when we studied the dose response on the T cell immunity,
there was a reduced efficacy at the highest doses in both mice and rats. This observation should not be
ignored. If the dose is too large, it could have a detrimental effect on vaccine efficacy. Considering
that the mouse is about 1/10th the size of a rat and the maximal T cell responses are found at 109
and 1010 vp/animal, this may not be coincidental. Another explanation could be that at very high
doses, there is a suppression of immunity by regulatory and suppressor T cells. We observed this
phenomenon in a previous study in which we continued to serotype switch rAd viruses expressing the
same vaccine immunogen [10,11]. In our previous study, the antibody responses began to decline after
the 3rd boost of helper-dependent rAd and the T cell responses declined after the 2nd boost. The dose
of the vaccine and the number of immunizations could play a significant role in the final immune
responses. However, as seen in this study, the immune correlates may not be predictive of protection
against infectious diseases. A recent study that examined the response to repetitive vaccination in
humans found that there was a significant reduction in hemagglutination inhibition titers after the
second immunization with an identical vaccine [47]. This study may shed light on why a high dose
and repeat vaccinations do not always induce typical anamnestic responses.
Interestingly, even though it appeared that immune correlates were significantly different between
the IM and IN immunized mice, the vaccine efficacy was almost identical. The top three vaccine doses
were insignificant for weight loss and exactly the same for survival. No differences were observed
until the vaccine doses were 1 × 106 vp/mouse or lower. This is a powerful demonstration that rAds
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are extremely effective at inducing immunity. A 5 × 106 virus particle vaccine dose may be as few as
5000 infectious particles and would easily be translatable to a human vaccine dose equivalent.
With regard to immune correlates, more vaccine is better for antibody responses, but there may
be a limit to T cell immunity and more vaccine is not always better. In view of the challenge study,
it should also be noted that immune correlates are not always predictive of protection against an
infectious virus, such as influenza virus. These data show that careful consideration should be given to
the dose of vaccine and route of immunization in studies that use rAd as a vaccine platform.
5. Conclusions
New and improved vaccines are essential for inducing protection against existing and emerging
infectious diseases. As molecular biology techniques have become streamlined, the ability to generate
and test rAd vaccines has increased tremendously. Most of these rAd vectored vaccines are first
analyzed in small animal rodent models for vaccine-induced immune responses and protection against
disease challenges. Here, we show that there is a need to standardize the doses and routes in which
these rAd vaccines are tested. Clearly, our data indicate that there are limits to correlations between
dose and response. Higher doses may not always correlate with higher immune correlates and higher
immune correlates may not always correlate with protection against an infectious disease. These data
may shed light on why some studies observed a decrease in immune correlates after repetitive boosting
or with high doses of vaccine. In addition, these data are likely to act as a guide for determining
optimal vaccine dose and route.
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